Articles from Orbital Therapeutics

Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo to treat disease at its source, today announced the appointment of Adam Raff, M.D., Ph.D., as Senior Vice President, Clinical Development. Dr. Raff will oversee Orbital’s clinical and regulatory strategy and execution and will serve as a key member of the company’s executive leadership team.

Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo to treat disease at its source, today announced encouraging preclinical results supporting the development of its lead RNA immunotherapy candidate, OTX-201, at the 5th Annual mRNA-Based Therapeutics Summit in Boston, held July 21–23, 2025. Specifically, in a non-human primate study, Orbital’s in vivo CAR-T approach achieved full B cell depletion in blood, spleen, and lymph nodes, which is required for an effective immune system reset in autoimmune disease. Based on preclinical findings to date, Orbital is advancing OTX-201 through IND-enabling studies and plans to begin clinical development in the first half of 2026.

Orbital Therapeutics, a company dedicated to enhancing global health by unleashing the full potential of RNA medicines, today announced the appointment of Geno Germano to its Board of Directors. Mr. Germano is a 35-year biopharma and life sciences industry veteran with extensive development and commercialization senior leadership experience across multiple therapeutic areas.

Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the appointment of Anna Dixon as senior vice president (SVP), human resources. Ms. Dixon will be responsible for all aspects of Orbital’s human resources operations and strategy, including talent acquisition, talent management and organization development, and will serve as a key member of the executive team.

Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the appointment of Ron Philip as chief executive officer (CEO) and a member of its board of directors. Mr. Philip brings to Orbital more than 30 years of biopharma leadership experience, including most recently as CEO of Spark Therapeutics, a member of the Roche Group. Mr. Philip succeeds founding CEO Giuseppe “Pino” Ciaramella, Ph.D., who will remain a scientific and strategic advisor to Orbital. Dr. Ciaramella is president of Beam Therapeutics, a strategic partner to Orbital.

Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the successful closing of $270 million Series A financing. The Series A raise was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and other undisclosed investors.

Orbital Therapeutics launched today with a vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.